GlobalData on MSN6d
FDA approves Roche’s Tecentriq Hybreza for cancer
The US Food and Drug Administration (FDA) has approved Roche's Tecentriq Hybreza, a subcutaneous anti-PD-(L)1 cancer ...
Business Wire6d
FDA Approves Genentech’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug ...
FiercePharma6d
After delay, Roche's Tecentriq Hybreza wins first FDA approval for a subcutaneous PD-L1 drug
It’s better late than never for an FDA approval for the first subcutaneous PD-L1 inhibitor, which was doled out to Roche’s ...
FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy
Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and ...
Managed Healthcare Executive6d
FDA Approves Subcutaneous Tecentriq to Treat Multiple Cancers
Tecentriq Hybreza can be administered over seven minutes, compared with 30 to 60 minutes for IV infusion of Tecentriq. There ...
The Pharma Letter6d
FDA greenlights Genentech’s Tecentriq Hybreza
The US Food and Drug Administration (FDA) has approved Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs), the first and ...
Yahoo Finance6d
FDA approves Roche’s Tecentriq Hybreza for cancer
The US Food and Drug Administration (FDA) has approved Roche's Tecentriq Hybreza, a subcutaneous anti-PD-(L)1 cancer immunotherapy. The treatment offers a quicker and more comfortable ...
Monthly Prescribing Reference6d
FDA Approves Tecentriq Hybreza, a Subcutaneously Administered PD-L1 Inhibitor
The Food and Drug Administration (FDA) has approved Tecentriq Hybreza ™ (atezolizumab and hyaluronidase-tqjs) for subcutaneous (SC) injection, for all the approved adult indications of intravenous ...
Roche Gets FDA Approval for Subcutaneous Formulation of Tecentriq
The FDA approves subcutaneous formulation of RHHBY's leading immunotherapy drug, Tecentriq, under the brand name Tecentriq ...
FDA Oks Genentech's Tecentriq Hybreza As First & Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy
Genentech, a member of the Roche Group (RHHBY), said Thursday that the U.S. Food and Drug Administration has approved Tecentriq ...